HomeCompareCIMEF vs ABBV

CIMEF vs ABBV: Dividend Comparison 2026

CIMEF yields 2.74% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CIMEF wins by $30.6K in total portfolio value· pulled ahead in Year 9
10 years
CIMEF
CIMEF
● Live price
2.74%
Share price
$1.41
Annual div
$0.04
5Y div CAGR
46.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$133.0K
Annual income
$51,361.74
Full CIMEF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CIMEF vs ABBV

📍 CIMEF pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCIMEFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CIMEF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CIMEF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CIMEF
Annual income on $10K today (after 15% tax)
$232.70/yr
After 10yr DRIP, annual income (after tax)
$43,657.48/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CIMEF beats the other by $22,601.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CIMEF + ABBV for your $10,000?

CIMEF: 50%ABBV: 50%
100% ABBV50/50100% CIMEF
Portfolio after 10yr
$117.7K
Annual income
$38,066.75/yr
Blended yield
32.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CIMEF
No analyst data
Altman Z
3.2
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CIMEF buys
0
ABBV buys
0
No recent congressional trades found for CIMEF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCIMEFABBV
Forward yield2.74%3.06%
Annual dividend / share$0.04$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR46.4%40.6%
Portfolio after 10y$133.0K$102.3K
Annual income after 10y$51,361.74$24,771.77
Total dividends collected$104.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CIMEF vs ABBV ($10,000, DRIP)

YearCIMEF PortfolioCIMEF Income/yrABBV PortfolioABBV Income/yrGap
1$11,101$400.78$11,550$430.00$449.00ABBV
2$12,487$608.72$13,472$627.96$985.00ABBV
3$14,297$936.84$15,906$926.08$1.6KABBV
4$16,766$1,467.71$19,071$1,382.55$2.3KABBV
5$20,294$2,354.87$23,302$2,095.81$3.0KABBV
6$25,615$3,900.08$29,150$3,237.93$3.5KABBV
7$34,143$6,735.20$37,536$5,121.41$3.4KABBV
8$48,817$12,283.38$50,079$8,338.38$1.3KABBV
9← crossover$76,263$24,029.11$69,753$14,065.80+$6.5KCIMEF
10$132,963$51,361.74$102,337$24,771.77+$30.6KCIMEF

CIMEF vs ABBV: Complete Analysis 2026

CIMEFStock

CIMC Enric Holdings Limited provides transportation, storage, and processing equipment for the clean energy, chemicals, environmental, and liquid food industries worldwide. Its Clean Energy segment manufactures and operates equipment for the storage, transportation, processing, and distribution of compressed natural gas trailers, seamless pressure cylinders, liquefied natural gas trailers and storage tanks, liquefied petroleum gas tanks and trailers, natural gas refuelling station systems, and natural gas compressors; and offers engineering, procurement, and construction services for the natural gas industry, as well as internet of things intelligent operation and management platform under the Anjiehui brand. It offers its products under the Enric, Sanctum, Hongtu, CIMC Tank, Cryobest, Hashenleng, YPDI, CIMC SOE, and CIMC Hydrogen brands. The company's Chemical and Environmental segment offers tank containers for the storage and transportation of liquefied or gasified chemicals under the CIMC Tank and Tankmiles brands. Its Liquid Food segment engineers, manufactures, and sells stainless steel tanks for storage and processing liquid food, such as beer, fruit juice and milk; and provides EPC services for brewery and other liquid food industries under the Ziemann Holvrieka, Briggs of Burton, McMillan, and DME brands. The company also manufactures compressors and accessories, and pressure vessels; offers business solutions for gas equipment; researches and develops technology for natural gas equipment; cryogenic storage and transportation equipment design, manufacture, and technical services; collects, processes, and sells renewable resources; offers terminal and depot, and nonmetallic scrap processing services; and repairs and maintains pressure vessels. The company was incorporated in 2004 and is headquartered in Shenzhen, the People's Republic of China. CIMC Enric Holdings Limited is a subsidiary of China International Marine Containers (Hong Kong) Limited.

Full CIMEF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CIMEF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CIMEF vs SCHDCIMEF vs JEPICIMEF vs OCIMEF vs KOCIMEF vs MAINCIMEF vs JNJCIMEF vs MRKCIMEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.